📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 18:33
298 analysed today
FollowTelegram
298
Today
149,699
All-time analysed
42,924
Positive
6,662
Negative
91,432
Neutral
8,613
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Astal Laboratories Q1 Cons. Revenue at ₹100.94 Cr; Standalone PAT Rises 77% YoY to ₹3.71 Cr
Astal Laboratories reported consolidated revenue from operations of ₹100.94 Cr (₹10,093.58 Lakhs) for the quarter ended June 30, 2026. On a standalone basis, revenue grew 56.0% YoY to ₹39.51 Cr from ₹25.33 Cr, with standalone net profit increasing 77.4% YoY to ₹3.71 Cr compared to ₹2.09 Cr in the previous year quarter. The company's wholly owned subsidiary, Sriven Pharmachem India Private Limited, contributed ₹61.53 Cr in revenue and ₹5.71 Cr in net profit during the quarter. The business operates in a single segment focused on the manufacturing and trading of Active Pharmaceutical Ingredients (Bulk Drugs).
Confidence: HIGH
What changedAstal Laboratories released its Q1 financial results, showing significant scale expansion from the consolidation of its subsidiary Sriven Pharmachem India.
Why it mattersThe inclusion of Sriven Pharmachem expands total quarterly revenue baseline to over ₹100 Cr, substantially boosting operational scale in the bulk drugs segment.
Consolidated Revenue: ₹10,093.58 LakhsStandalone Revenue: ₹3,951.47 LakhsStandalone PAT: ₹370.69 LakhsSubsidiary Revenue Contribution: ₹6,152.77 LakhsSubsidiary PAT Contribution: ₹571.48 Lakhs
📅 Short termEarnings show healthy standalone YoY growth and scale expansion from subsidiary integration, which may support near-term sentiment.
📈 Long termSustainable long-term performance hinges on profitability in the API business and stability in corporate governance given the low promoter stake.
⚠ Risk flags
- Significantly low promoter holding (4.53% as of June 2026, down from 18.19% in Dec 2025)
- High concentration of consolidated revenue in the subsidiary Sriven Pharmachem (>60% of total)
Key Highlights
Consolidated revenue from operations stood at ₹100.94 Cr (₹10,093.58 Lakhs) for Q1 ended June 30, 2026.
Standalone revenue increased 56.0% YoY to ₹39.51 Cr from ₹25.33 Cr in the corresponding quarter of the previous year.
Standalone net profit grew 77.4% YoY to ₹3.71 Cr (₹370.69 Lakhs) vs ₹2.09 Cr (₹208.96 Lakhs) in Q1 FY26.
Subsidiary Sriven Pharmachem India contributed ₹61.53 Cr in revenue and ₹5.71 Cr in net profit for the quarter.
👀 What to Watch
Monitor whether the consolidated revenue run-rate above ₹100 Cr and subsidiary margins sustain in upcoming quarters, alongside tracking the low promoter shareholding.
Astal Laboratories Reports Q1 Consolidated Revenue of ₹100.94 Cr and PAT of ₹9.42 Cr
Astal Laboratories approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. On a consolidated basis, revenue from operations stood at ₹100.94 Cr, driven heavily by its wholly owned subsidiary Sriven Pharmachem India Pvt Ltd, which contributed ₹61.53 Cr in revenue and ₹5.71 Cr in PAT. Standalone revenue came in at ₹39.51 Cr with a net profit of ₹3.71 Cr, up 77.4% YoY compared to ₹2.09 Cr in the previous year quarter. Paid-up equity capital stood at ₹43.80 Cr.
Confidence: HIGH
What changedAstal Laboratories reported its quarterly financial results showing significant consolidated scale post-acquisition/integration of Sriven Pharmachem.
Why it mattersThe company's scale is now substantially expanded with the subsidiary contributing over 60% of consolidated revenue, reflecting a structural shift in operations.
Consolidated Revenue (Q1): ₹10,093.58 LakhsStandalone Revenue (Q1): ₹3,951.47 LakhsStandalone PAT (Q1): ₹370.69 LakhsSubsidiary PAT (Sriven Pharmachem): ₹571.48 LakhsEquity Capital: ₹4,379.89 Lakhs
📅 Short termEarnings show strong YoY standalone growth and healthy consolidated revenue, which may support positive sentiment in the near term.
📈 Long termSustained performance will depend on the continued integration and margin profile of the API/bulk drug business and performance of Sriven Pharmachem.
⚠ Risk flags
- Promoter holding is low at 4.53% (down from 18.19% in Dec 2025).
- High dependence on single subsidiary Sriven Pharmachem for over 60% of consolidated revenue.
Key Highlights
Consolidated revenue from operations reached ₹10,093.58 Lakhs (₹100.94 Cr) for Q1 ended June 30, 2026.
Wholly owned subsidiary Sriven Pharmachem contributed ₹6,152.77 Lakhs in revenue and ₹571.48 Lakhs in net profit.
Standalone revenue from operations rose 56.0% YoY to ₹3,951.47 Lakhs compared to ₹2,532.66 Lakhs in Q1 previous year.
Standalone PAT surged to ₹370.69 Lakhs, up from ₹108.59 Lakhs in the preceding quarter and ₹208.96 Lakhs in Q1 previous year.
👀 What to Watch
Track the performance and margin stability of the core bulk drug/API operations as well as subsequent quarterly contributions from subsidiary Sriven Pharmachem.
